GlassScriptPhysician profile
Phillip Joseph Gaca
NPI 1912999210
$11,873.06
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,116 · 2020: $1,661 · 2021: $2,622 · 2022: $2,871 · 2023: $2,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,604.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,475.69 | 2019-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,465.92 | 2019-2023 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,250.01 | 2019-2023 | Stiolto Respimat, Spiriva Respimat, Jardiance |
| Novo Nordisk INC | $1,085.23 | 2019-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $920.57 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $633.34 | 2021-2023 | |
| Lilly USA, LLC | $552.17 | 2019-2023 | Mounjaro |
| Amarin Pharma, INC. | $539.27 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $423.01 | 2019-2023 | |
| Abbvie INC. | $413.26 | 2021-2023 | |
| Mylan Specialty L.P. | $295.10 | 2019-2023 | Yupelri |
| Vanda Pharmaceuticals INC. | $291.84 | 2021-2023 | Hetlioz, Fanapt |
| Astellas Pharma US INC | $291.20 | 2019-2023 | Veozah |
| Supernus Pharmaceuticals, INC. | $240.49 | 2019-2020 | Xyosted |
| Pfizer INC. | $223.47 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Gaca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.